Skip to content

Price / book at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
6.2×-1.0×
Cytokinetics logo
CytokineticsCYTK
58.5×
Catalyst Pharmaceutical logo
Catalyst PharmaceuticalCPRX
-0.7×
Dyne Therapeutics, Inc. logo
Dyne Therapeutics, Inc.DYN
3.5×+1.7×
Viking Therapeutics logo
Viking TherapeuticsVKTX
7.5×+4.3×
Scholar Rock logo
Scholar RockSRRK
20.5×+10.7×

Other financials

Income statement

See full
Operating income-$54.1M-17.7%
Net income-$49.0M-20.1%
EPS (diluted)-$0.46-7.0%

Balance sheet

See full
Cash & equivalents$33.2M-33.5%
Total debt$3.8M-16.8%
Total equity$493.2M+14.8%
Total assets$518.5M+14.1%

Cash flow

See full
Operating cash flow-$42.5M-12.4%
CapEx$260.0K+491%
Free cash flow-$42.8M-12.9%

Valuation

See full
Market cap$3.96B+61.3%
Enterprise value$3.93B+63.5%

Returns & leverage

See full
Return on equity-38.1%+13.4pp
Debt / equity0.0×
Current ratio22.6×+1.6×

Where this comes from

Calculated from Edgewise Therapeutics, Inc.’s reported figures.

Based on the most recent quarter.

The official record: Edgewise Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Edgewise Therapeutics, Inc.'s price / book.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Edgewise Therapeutics, Inc.'s price / book?
Edgewise Therapeutics, Inc. (EWTX) reported price / book of 6.9× in Q1 2026.
How has Edgewise Therapeutics, Inc.'s price / book changed year-over-year?
Edgewise Therapeutics, Inc.'s price / book increased by 40.6% year-over-year, from 4.9× to 6.9×.
What is the long-term trend for Edgewise Therapeutics, Inc.'s price / book?
Over 4 years (2021 to 2025), Edgewise Therapeutics, Inc.'s price / book has grown at a 16.2% compound annual growth rate (CAGR), from 2.8× to 5×.
What does price / book mean?
Market capitalization at the quarter end divided by shareholders' equity. The premium (or discount) the market assigns to the company's book equity.